Fosfomycin-induced liver injury in a 17-year-old patient: A case report

Clicks: 1
ID: 316500
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #119 of 143 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 143 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: To describe a case of severe acute hepatitis in an adolescent in whom fosfomycin was identified as the highly probable cause of drug-induced liver injury (DILI) and to highlight the potential hepatotoxicity of fosfomycin. SUMMARY: A previously healthy 17-year-old male presented with nausea, vomiting, fever, and progressive epigastric pain over 3 days, accompanied by fatigue and malaise. Laboratory testing revealed marked hepatocellular injury, coagulopathy, metabolic acidosis, mild pre-renal acute kidney injury, and elevated inflammatory markers. Imaging demonstrated hepatomegaly with ascites, without biliary obstruction or vascular abnormalities. Extensive evaluation excluded viral hepatitis, autoimmune liver disease, Wilson's disease, ischemic hepatitis, zoonotic infections, and other potential hepatotoxic exposures. Within the 15 days before symptom onset, the patient had completed a 7-day course of oral fosfomycin 500 mg every 8 hours for renal colic-associated dysuria, with no other medications linked to liver injury. Clinical deterioration with hypotension and oliguria required admission to the intensive care unit, where the patient improved with supportive management during a 4-day stay. Using the Roussel-Uclaf Causality Assessment Method (RUCAM), the score was 9, indicating a highly probable association between fosfomycin and the liver injury. Levels of liver enzymes gradually normalized, and the patient was discharged with full recovery. CONCLUSION: Although fosfomycin is widely used and generally well tolerated, clinicians should remain vigilant for this rare but potentially serious adverse effect. Early recognition and prompt discontinuation of the suspected agent are essential. Reporting uncommon adverse reactions helps strengthen pharmacovigilance and supports safer therapeutic decision-making.
Reference Key
openalex_W7164085209 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Estefanía Palazón Gonzálvez, María Dolores Nájera Pérez, Roser Alegría Samper
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag162
URL
https://doi.org/10.1093/ajhp/zxag162
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.